Loading patent…
AssigneeHuman Genome Sciences, Inc.
InventorsTheodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
Estimating the term…
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
An isolated antibody or fragment thereof comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:
An isolated antibody or fragment thereof comprising:
The antibody expressed by the cell line of ATCC Deposit PTA-3570.
The antibody expressed by the cell line of ATCC Deposit PTA-3571.
The antibody expressed by the cell line of ATCC Deposit PTA-3675.
Dependencies are inferred from the claim text.